ArborGen Holdings Limited ArborGen Holdings Limited (NZX: ARB.NZ) is a New Zealand-based holding company that operates as a global leader in advanced forestry genetics, primarily through its wholly owned subsidiary ArborGen, providing genetically improved tree seedlings to the commercial forestry industry. The company offers a range of high-value products including conventional and advanced genetic seedlings for species such as loblolly pine, slash pine, longleaf pine, radiata pine, and eucalyptus; these seedlings feature enhanced growth rates, yields, stress tolerance, disease resistance, and wood quality, produced across 14-16 commercial-scale nurseries and 10 seed orchards with an annual capacity of approximately 450-500 million seedlings, serving over 2,000 customers annually in key markets including the US South and Brazil. Operations focus on the forestry genetics segment, with additional engagement in emerging carbon markets through protocol development with carbon registries; facilities include world-class research centers in Summerville and Ridgeville, South Carolina, USA, multiple nurseries throughout the southeastern United States, and production sites in Brazil such as Telêmaco Borba and a new site in Teresina. Founded in 2001 and headquartered at 100 Parnell Road, Auckland, New Zealand, the company rebranded from Rubicon Limited in September 2019 to reflect its focus on ArborGen's core operations following the divestment of New Zealand and Australian businesses in 2021. Recent major developments include the completion of the USD$4 million sale of its in vitro services business in July 2024 to reduce debt and fund growth; the signing of a memorandum of understanding in October 2024 to acquire the Eco Empreendimentos nursery in Piauí, Brazil, for approximately USD$2.5 million to expand footprint; an acquisition of a eucalyptus nursery in Erval Grande, Brazil, in 2023; a share buyback program completed in January 2025 returning up to US$500,000 in capital; the appointment of a new Chief Financial Officer in 2024 and leadership changes including a new CEO in 2023; and strong FY25 results announced in May 2025 in line with guidance, alongside FY26 outlook emphasizing market opportunities in advanced genetics and carbon sequestration.